releases: https://www.tillis.senate.gov//public/index.cfm/press-releases?ContentRecord_id=8B41E5C0-02EC-4811-947F-F33D79C0D3C7
Data license: MIT · Data source: dwillis/congress-press
This data as json
| url | title | date | year | month | party | chamber | state | member_name | bioguide_id | domain | scraper | source | date_source | text | has_text | collected_at | updated_at |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| https://www.tillis.senate.gov//public/index.cfm/press-releases?ContentRecord_id=8B41E5C0-02EC-4811-947F-F33D79C0D3C7 | Tillis Statement on FDAs Announcement on Tobacco and Vapor Products | 2018-11-16 | 2018 | 2018-11 | Republican | House | NC | Thom Tillis | T000476 | www.tillis.senate.gov | legacy | WASHINGTON, D.C. Today, Senator Thom Tillis (R-NC) issued the following statement on the FDA's recent announcement on tobacco and vapor products: I applaud the FDA's commitment to developing a robust plan to combat underage use of e-vapor products. However, I hope the FDA revisits some of its actions affecting traditional products that have been marketed for decades. The FDA must remain committed to using a science-based regulatory framework in order to effectively reduce risks and minimize collateral damage that would ultimately limit options available to adults seeking an alternative to smoking. ### | 1 | 2026-03-30T12:14:52Z | 2026-03-30T12:14:52Z |